FDA Approves Exact Sciences' Colorectal Cancer Screening Test Cologuard Plus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 04 2024
0mins
Source: Business Insider
FDA Approval: Exact Sciences Corp. received FDA approval for its Cologuard Plus test, a non-invasive stool DNA test for colorectal cancer screening, demonstrating high sensitivity and specificity based on the BLUE-C study results.
Launch Plans: The company plans to launch the Cologuard Plus test in 2025, aiming to improve cancer detection rates and reduce false positives among the 60 million Americans who are not current with their screenings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
